SDK001 holds the promise of removing the burden of frequent intravenous infusions. Click here to learn more about our science and how SDK001 treatment could re-imagine the patient experience in APL
SDK Therapeutics is a new, privately-held company, committed to bringing to market innovations that improve the lives of patients diagnosed with APL and other diseases.
